News Focus
News Focus
Replies to #99353 on Biotech Values
icon url

marthambles

07/23/10 11:22 AM

#99354 RE: DewDiligence #99353

nvs hasn't moved that much. I wonder if the news has not sunk in, or if the benefit to NVS is considered too insignificant.
icon url

alertmeipp

07/23/10 11:23 AM

#99355 RE: DewDiligence #99353

The approval will make Copaxone, M118 and thus MNTA way more valuable.

Big pharms which like to expand their generic pipeline will love to buyout MNTA even at a high premium.
icon url

jbog

07/23/10 11:25 AM

#99356 RE: DewDiligence #99353

Dew, Well 4% of Teva is about $1.9 billion. If they gave that value to mnta today we're talking $50 ish.

Won't happen unless the 3.8 mil shorts head for the door at once.